If you’re into biotech stock opportunities, you know the sector has been suppressed lately:
XBI, a broad-based biotech ETF
That’s due to some macro factors – including the ability to find patients and the costs of the trials.
Now that interest rates are starting to ease, it may attract more institutional investment into the space…
And we just spotted one name that’s teeing up for a textbook continuation trade.
Take a look:
The stock had a strong gap up this summer on a solid FDA event. Then they announced a secondary offering to fund further operations.
That’s the trickiest part of a transition from a “trial” FDA company to a bigger one. When you have good data, you raise capital and introduce shares onto the market, which could affect price.
But if there is enough institutional appetite, the stock will continue to hold its levels – which is exactly what’s happening here.
It’s a straightforward momentum continuation play… and our stock roadmap tells us everything we need to know about the opportunity here.
Institutions – the so-called smart money – have accepted and absorbed these higher prices. That provides a path for even higher prices, because when you have persistent institutional demand with dwindling stock supply, the market must auction higher to find fresh sellers.
It’s the same setup that’s helped us see gains like 433%, 527%, even 3,400% in just 90 days…
Click here to learn more in a free presentation.
Original Post Can be Found Here